Genomictree (228760.KQ) Stock Price

Genomictree Price

CLOSED
9,500.00
​
Market closed

Revenue has compounded at 13.6% per year over the past 10 years to 3.76 B KRW. Genomictree's net margin stands at -239.0%, down from -222.3% several years earlier.

Genomictree stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomictree business model & stock analysis

Genomictree Inc is a biotechnology company based in Daejeon, South Korea, operating within the Health Care sector. The company went public through an IPO on July 19, 2016, and is listed under the ticker 228760.KQ with ISIN KR7228760005. Genomictree develops and supplies diagnostic products focused on cancer screening and prognosis. Its services include genomic analysis using microarray technology and next-generation sequencing. The company conducts clinical trials for molecular diagnostic products, which encompass both cancer-related and genetic diagnostic solutions. Cancer molecular diagnostic products cover various malignancies, including colorectal, bladder, lung, stomach, and cervical cancers. Additionally, Genomictree offers molecular genetic diagnostic products, such as epidermal growth factor receptor (EGFR) mutation detection and human papillomavirus (HPV) diagnostic tests. The company's website is http://www.genomictree.com/. Genomictree operates in the biotechnology industry, specializing in molecular diagnostics for healthcare applications. It provides diagnostic tools aimed at improving early detection and treatment planning for cancer patients. The firm's product portfolio includes both in vitro diagnostic solutions and genomic analysis services. Genomictree's focus on cancer diagnostics aligns with global efforts to enhance precision medicine and personalized healthcare strategies. The company is headquartered in Daejeon, a city known for its research and development infrastructure in South Korea. Genomictree's operations are centered around developing innovative diagnostic technologies to support clinical decision-making and patient outcomes.

Frequently asked questions about Genomictree

5 analysts currently rate the Genomictree stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Genomictree to generate revenue of 7.80 B KRW and earnings per share of -141.17 KRW.

Converted at the current exchange rate, the Genomictree share trades at 6.33 EUR (9,500.00 KRW).

The expected revenue of Genomictree is 7.80 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Genomictree is -3.46 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Genomictree is currently -67.30. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Genomictree stock.

The price-to-sales ratio (P/S) of Genomictree is currently 29.87. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Genomictree stock.

The Eulerpool Quality Score for Genomictree is 2/10.

The ISIN of Genomictree is KR7228760005. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Genomictree is 228760.KQ. The ticker symbol is used to trade Genomictree shares on the stock exchange.

Fair ValueTerminal
7,790.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
Jul 19, 2016
ISIN
KR7228760005
Cusip
Y2R9RK107
Market capitalization
226.85 B KRWMega Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-67.30
P/Se
29.87
EV/EBIT
—
P/B Ratio
1.97
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-7.81 %
Last updated Oct 18, 2026, 8:38 AM

Genomictree Peer Group

Genomictree FIGI

228760:KS · BBG00DBKVJW3228760:KQ · BBG00DBKVJY1

All fundamentals and in-depth analysis of Genomictree

Our stock analysis for Genomictree stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genomictree. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.